two competition updates on Angelman and Prader Willi to follow:
https://ir.ultragenyx.com/news-rele...pipeline-update-analyst-day-monday-october-16
Panel discussion on GTX-102 for the treatment of Angelman syndrome (AS)
Elizabeth Berry-Kravis our old acquaintance!!!
- Elizabeth Berry-Kravis, M.D., Ph.D., Professor, Department of Pediatrics, RUSH Medical College, and principal investigator for GTX-102 Phase 1/2 study
- Kemi Olugemo, M.D., F.A.A.N., vice president of global clinical development at Ultragenyx
Then Harmony Biosciences (which is currently acquiring Zynerba Fragilex cannabinoids) updates us on Prader Willi:
https://www.prnewswire.com/news-rel...nts-with-prader-willi-syndrome-301947886.html
https://www.harmonybiosciences.com/...iences-to-acquire-zynerba-pharmaceuticals-inc
THE COMPETITION OF 2591
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.27 |
Change
0.920(6.41%) |
Mkt cap ! $1.951B | |||
| Open | High | Low | Value | Volume |
| $14.35 | $15.27 | $14.35 | $8.720M | 579.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $15.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.27 | 3638 | 4 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |